Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,604.47
(
0.32%
)
US TECH 100
29,715.62
(
0.62%
)
Dow Jones
51,115.07
(
0.16%
)
Brent Oil
94.87
(
3.84%
)
Bitcoin
71,494.00
(
-2.80%
)
News Focus
News Focus
Post# of 257675
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123046
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 213839

Wednesday, 09/27/2017 2:29:37 PM

Wednesday, September 27, 2017 2:29:37 PM

Post# of 257675
(ADXS)—ADRO is yet another neoantigen competitor:

https://globenewswire.com/news-release/2017/09/27/1133689/0/en/Aduro-Biotech-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Personalized-Immunotherapy-pLADD-Based-on-Proprietary-Neoantigen-Technology.html

The single indication in ADRO’s phase-1 trial is second-line colorectal cancer.

ADXS NEO’s phase-1, which has not yet enrolled any patients (#msg-134670005), will (purportedly) be tested in NSCLC, H&N cancer, and CRC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today